Ubicación: Global + English
Global Global Algérie Français Algeria English Angola Português Angola English Argentina Español Argentina English Australia English Austria Deutsch Austria English Azerbaijan English Azerbaijan Русский Bahrain English Bangladesh English Belgium English Belgium Français Belgium Nederlands Brazil Português Brazil English Bulgaria български Bulgaria English Cameroon English Cameroon Français Canada English Canada Français Chile Español Chile English China 中文 China 日本語 China English Colombia Español Colombia English Croatia English Czech Republic Čeština Czech Republic English Denmark English Djibouti English Ecuador Español Ecuador English Egypt English Estonia English Ethiopia English Finland Suomi Finland English France Français France English Georgia English Georgia Русский Germany Deutsch Germany English Ghana English Greece Ελληνικά Greece English Guatemala Español Guatemala English Hong Kong, China English Hong Kong, China 中文 Hungary Magyar Hungary English India English Indonesia English Iraq English Ireland English Italy Italiano Italy English Ivory Coast Français Ivory Coast English Japan 日本語 Japan English Jordan English Kazakhstan Русский Kazakhstan English Kenya English Kuwait English Kyrgyzstan Русский Kyrgyzstan English Latvia English Lithuania English Malaysia English Mauritius English Mauritius français (Maurice) Mexico Español Mexico English Moldova Română Moldova English Mongolia English Morocco English Morocco Français Mozambique Português Mozambique English Netherlands Nederlands Netherlands English New Zealand English Nigeria English Norway English Oman English Pakistan English Paraguay Español Paraguay English Peru Español Peru English Philippines English Poland Polski Poland English Portugal Português Portugal English Qatar English Republic of Korea 한국어 Republic of Korea English Romania Română Romania English Saudi Arabia English Serbia Српски Serbia English Singapore English Slovakia English Slovenia English South Africa English Spain English Spain Español Sri Lanka English Sweden English Switzerland Deutsch Switzerland Français Switzerland Italiano Switzerland English Tanzania English Thailand ไทย Thailand English Togo English Togo Français Tunisia English Tunisia Français Türkiye Türkçe Türkiye English Turkmenistan Русский Turkmenistan English Ukraine Українська Ukraine English United Arab Emirates English United Kingdom English Uruguay Español Uruguay English USA English Uzbekistan English Uzbekistan Русский Vietnam Tiếng Việt Vietnam English

HPLC Related Substances Determination: Principles, Methods, and Regulatory Requirements

HPLC related substances determination is a critical quality control test used to identify and quantify impurities in pharmaceutical drug substances and drug products through liquid chromatography analysis. This testing ensures compliance with international regulatory thresholds defined by ICH guidelines and major pharmacopoeias, safeguarding product safety, efficacy, and stability. This article provides a comprehensive technical overview of related substances testing, including sample types, analytical methods, validation requirements, and practical applications.

Technical Overview

Related substances determination by high-performance liquid chromatography (HPLC) is one of the most important analyses in pharmaceutical quality control. Related substances refer to chemical impurities that are structurally related to the active pharmaceutical ingredient (API), including synthesis intermediates, starting materials, reagents, catalysts, by-products, and degradation products formed during manufacturing or storage. Because these impurities may affect product safety, efficacy, and stability, regulatory authorities worldwide require their systematic monitoring and control.

In a typical related substances test, the sample is separated on a chromatographic column, and each impurity is detected as an individual peak in the chromatogram. The position of each peak, expressed as relative retention time (RRT) or retention time, and the peak area are compared against reference standards and validated acceptance criteria. Photodiode array (PDA) detectors are widely used to assess peak purity, confirming that the API peak and impurity peaks are chromatographically pure and free from co-elution.

The regulatory framework for this testing is established by the ICH Q3A(R2) guideline for impurities in new drug substances and ICH Q3B(R2) for impurities in new drug products, which define reporting, identification, and qualification thresholds based on the maximum daily dose. Complementary requirements are specified in major pharmacopoeias, including the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the Japanese Pharmacopoeia (JP), and the Chinese Pharmacopoeia (ChP, published under the GB framework). Accredited third-party laboratories perform this testing in accordance with these recognized standards to support regulatory submissions and routine quality control.

Testing Samples

Drug Substances (Active Pharmaceutical Ingredients)

Synthetic, semi-synthetic, or purified APIs are tested to characterize process-related impurities and establish baseline impurity profiles. The impurity profile of a drug substance directly determines the specifications applied to the finished drug product, making this the starting point of any impurity control strategy.

Drug Products

Finished dosage forms, including tablets, capsules, injectable solutions, powders, oral suspensions, ointments, and topical formulations, are tested for degradation products arising from API decomposition, API-excipient interaction, or manufacturing stress. Sample preparation typically involves extraction of the API and impurities from the dosage form matrix with a suitable solvent, followed by filtration or centrifugation before injection.

Process Intermediates and Starting Materials

In-process control samples, key intermediates, and starting materials may be evaluated to trace the origin of impurities, verify purge factors across synthetic steps, and support process development and optimization studies.

Stability Study Samples

Samples stored under ICH Q1A(R2) conditions, including long-term, intermediate, and accelerated storage, as well as stress-tested samples from forced degradation studies, are analyzed to monitor impurity growth over time and establish retest periods and shelf life.

Testing Items

The related substances determination typically includes the following measurable parameters:

  • Specified identified impurities: known impurities with confirmed structures, quantified against certified reference standards with defined acceptance limits.
  • Specified unidentified impurities: impurities recognized by consistent relative retention time but not structurally identified, limited by RRT-based acceptance criteria.
  • Any individual unspecified impurity: each unknown impurity peak controlled at the reporting threshold, typically 0.05–0.10% depending on daily dose.
  • Total impurities: the sum of all impurity peak responses above the reporting threshold, controlled by a total impurities limit.
  • Total degradation products: the sum of degradation-related peaks, reported separately from process impurities in stability studies.
  • Peak purity assessment: spectroscopic evaluation across the API peak using PDA detection to confirm the absence of co-eluting impurities.
  • Chiral impurities: enantiomeric impurities, when applicable, determined using chiral stationary phases as a complementary method.

Testing Methods

Reversed-phase HPLC (RP-HPLC) is the predominant technique for related substances analysis. A validated chromatographic method typically employs a C18 or C8 column with gradient elution using a mobile phase of buffer and organic modifier such as acetonitrile or methanol. Detection is performed by UV at a wavelength selected from API and impurity UV spectra, commonly in the range of 210–280 nm. PDA detectors are preferred because they enable simultaneous multi-wavelength monitoring and peak purity analysis.

Quantification Approaches

Several quantification strategies are accepted, depending on the availability of impurity reference standards:

  • External standard method using certified impurity reference standards, providing the highest accuracy for known impurities.
  • Diluted sample comparison method, in which impurity peak responses are compared with the API peak response from a diluted standard solution, corrected by relative response factors (RRF).
  • Area normalization method, suitable only when all components exhibit similar response factors and are fully eluted and detected.

Method Validation

Methods are validated in accordance with ICH Q2(R2), supported by analytical procedure development principles in ICH Q14. Key validated parameters include:

  • Specificity: demonstrated through forced degradation studies under acid, base, oxidative, thermal, photolytic, and humidity stress conditions, with mass balance evaluation and peak purity confirmation.
  • Linearity: correlation coefficient typically not less than 0.999 over the range from the quantitation limit to at least 120% of the specification limit.
  • Accuracy: recovery within 80–120% at the quantitation limit level and 90–110% at higher concentration levels for impurities.
  • Precision: repeatability RSD typically not more than 10% at impurity levels, verified across independent preparations.
  • Limit of detection and limit of quantitation: established at signal-to-noise ratios of approximately 3 and 10, respectively, ensuring the LOQ does not exceed the reporting threshold.
  • Range, robustness, and solution stability: verified to ensure reliable performance under minor variations of method parameters.

System Suitability

Before sample analysis, system suitability is confirmed using a mixture of API and impurity standards or a stressed sample. Typical criteria include resolution between the API and the closest impurity peak of not less than 1.5, tailing factor not more than 2.0, adequate theoretical plates, and RSD of replicate standard injections not more than 2% (or 5% for low-level impurity standards). Only when all suitability criteria are met is the chromatographic system considered qualified for the determination.

Applications

HPLC related substances determination supports a wide range of pharmaceutical development and manufacturing activities:

  • Batch release testing: verification that commercial batches meet registered impurity specifications before distribution.
  • Stability programs: monitoring impurity growth under long-term and accelerated conditions to establish shelf life and storage conditions.
  • Regulatory submissions: generating impurity data for drug master files, new drug applications, and generic submissions in accordance with ICH thresholds.
  • Process development: comparing impurity profiles across synthetic routes, optimizing purification steps, and demonstrating impurity purge.
  • Out-of-specification investigations: root cause analysis of abnormal impurity peaks, including retention time shifts, new impurity identification, and corrective action evaluation.
  • Method transfer and comparability studies: demonstrating equivalence between developing and receiving laboratories or between original and modified methods.
  • Generic and biosimilar development: establishing impurity profiles comparable to the reference listed product.

FAQ

What is the difference between related substances and degradation products?

Related substances encompass all impurities structurally related to the API, including process-related impurities from synthesis and degradation products from decomposition. Degradation products are therefore a subset of related substances formed during manufacturing, storage, or use, and they are emphasized in stability studies.

How are acceptance limits for impurities established?

Limits are derived from ICH Q3A(R2) and Q3B(R2) reporting, identification, and qualification thresholds, which depend on the maximum daily dose of the API. Known toxic impurities are controlled at substantially tighter limits based on safety data, while qualified impurities are limited at levels supported by toxicological or clinical exposure.

Why is a PDA detector recommended for this test?

A PDA detector records full UV spectra across each chromatographic peak, enabling peak purity analysis to detect co-eluting impurities beneath the API peak, confirming method specificity, and allowing multi-wavelength reporting in a single run.

What sample quantity and form are required for testing?

Typically, a few hundred milligrams of drug substance or an equivalent number of dosage units are sufficient. Samples should be representative of the batch and submitted with structural information, the intended method or pharmacopoeial monograph, and any available impurity reference standards to ensure accurate quantification.

Can a single method detect all impurities?

In most cases, one well-developed RP-HPLC method can separate and quantify the majority of impurities. However, orthogonal methods, such as chiral HPLC for enantiomeric impurities, ion chromatography for inorganic impurities, or LC-MS for unknown impurity identification, may be required for complete impurity characterization.

How are unknown impurities handled when they exceed thresholds?

When an unidentified impurity exceeds the identification threshold, structural elucidation is performed using LC-MS/MS and preparative isolation with NMR. The identified impurity is then qualified through toxicological assessment or controlled through process optimization, and the method is updated with a corresponding reference standard and relative response factor.

Why Choose ZKGX?

  • State-of-the-art analytical equipment
  • Highly qualified scientific team
  • Fast turnaround time
  • Competitive pricing